Hepatocellular Carcinoma Excellence Forum

Hepatocellular Carcinoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Riccardo Lencioni, MD, University of Pisa School of Medicine

Videos

Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS

01/23/2024

Riccardo Lencioni , MD;

Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.

Ricardo Lencioni, MD, shares...

01/23/2024

Oncology

Quiz

STRIDE vs Sorafenib for Unresectable Hepatocellular Carcinoma

10/05/2023

Which treatment was associated with a better chance of survival at 4 years for patients with unresectable hepatocellular carcinoma?

Which treatment was associated...

10/05/2023

Oncology

Bruno Sangro, MD, PhD, Clínica Universidad de Navarra

Videos

Long-Term OS Benefit of STRIDE Regimen Among Patients With Unresectable Hepatocellular Carcinoma

08/21/2023

Bruno Sangro , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Bruno Sangro, MD, PhD, discusses 4-year overall survival results from the phase 3 HIMALYA study.

At the 2023 World Congress on...

08/21/2023

Oncology

Laura Dawson, MD, Princess Margaret Cancer Center

Videos

Stereotactic Body Radiotherapy Plus Sorafenib Improved Survival Outcomes for Patients With Hepatocellular Carcinoma Compared to Sorafenib Alone

01/20/2023

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares updated data from the NRG/RTOG 1112 trial evaluating stereotactic body radiotherapy plus sorafenib compared with sorafenib for hepatocellular carcinoma.

At the 2023 ASCO...

01/20/2023

Oncology

Videos

Palliative Radiotherapy Improves Pain for Patients With Symptomatic Hepatocellular Carcinoma and Liver Metastases

01/20/2023

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares results from a study evaluating palliative radiotherapy for hepatocellular carcinoma and liver metastases.

At the 2023 ASCO...

01/20/2023

Oncology

Andrea Casadei-Gardini, MD, San Raffaele Hospital

Videos

Lenvatinib Demonstrates Significant Benefit vs Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

07/02/2022

Andrea Casadei-Gardini, MD, discusses findings from an international study examining atezolizumab plus bevacizumab vs lenvatinib or sorafenib in patients with non-viral unresectable hepatocellular carcinoma.

Andrea Casadei-Gardini, MD,...

07/02/2022

Oncology

Videos

Liver Transplant Associated With Improved OS vs Systemic Therapy Alone for Non-Metastatic Hepatocellular Carcinoma

07/02/2022

Firas Baidoun, MD, discusses findings from a study that compared survival outcomes between upfront liver transplant, liver transplant with bridge systemic therapy, and systemic therapy only, for non-metastatic hepatocellular carcinoma.

Firas Baidoun, MD, discusses...

07/02/2022

Oncology

Videos

Integrating New Agents into the Treatment of HCC

08/12/2020

Ghassan Abou-Alfa, MD, discusses integrating novel agents into treatment of hepatocellular carcinoma at the virtual 2020 ESMO World GI meeting.

Ghassan Abou-Alfa, MD, discusses...

08/12/2020

Oncology

Videos

Systemic and Local Therapy Updates in HCC

07/09/2020

Ghassan Abou-Alfa, MD, discusses systemic and local therapy updates in hepatocellular carcinoma in the third part of this interview highlighting abstracts of note presented at the virtual 2020 ASCO Annual Meeting.

Ghassan Abou-Alfa, MD, discusses...

07/09/2020

Oncology

Videos

Deborah Mukherji, MD, Talks Gaps in Research and Potential for Further Study on HCC, Biliary Tract Cancers

07/04/2020

Dr Mukherji summarizes 3 posters that were presented at the virtual ESMO World Congress on GI Cancer, which identify gaps in research and can inform future biliary tract cancer trials.

Dr Mukherji summarizes 3 posters...

07/04/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology